0908 ET - Abbott Laboratories' fourth-quarter results are disappointing, JPMorgan analysts say in a research note, as organic growth came in meaningfully below expectations. The healthcare-products maker also issued a soft outlook for the current year, they add. There's a lot to unpack, the analysts say, noting in particular that Abbott's nutrition business drove the bulk of the weakness, that the company's medical-device unit generally performed well despite soft diabetes and electrophysiology sales, and that its diagnostics unit did better than expected despite still missing expectations. The analysts will be looking for more details on the call. Abbott shares fall 7% premarket. (connor.hart@wsj.com)

(END) Dow Jones Newswires

January 22, 2026 09:08 ET (14:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.